Latest Aktis Oncology News & Updates

See the latest news and media coverage for Aktis Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.

Aktis Oncology

Biotechnology company developing targeted alpha radiopharmaceuticals

aktisoncology.com

Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Aktis Oncology

In short: Aktis Oncology reported a $24.1 million Q2 loss, advanced its radiopharmaceutical pipeline, and raised $318 million through an IPO.

Company announcements

August 13 Aktis Oncology

Aktis Oncology reports Q2 2026 financial results and highlights

Cash stands at $517.3 million, funding operations into 2029. Phase 1b trials for AKY-1189 and AKY-2519 are enrolling, with data expected in 2027.

May 22 Aktis Oncology

Aktis Oncology reports first-in-human imaging data for AKY-2519

Data show robust tumor uptake and limited normal tissue exposure in B7-H3 expressing tumors, with potential differentiated profile.

May 4 Aktis Oncology

Aktis Oncology reports Q1 2026 financial results and highlights

Following its IPO, the company reported a net loss of $18.3 million, cash of $538.5 million, and clinical trial initiations for AKY-2519.

March 30 Aktis Oncology

Aktis Oncology announces FDA clearance for AKY-2519 and 2025 results

AKY-2519, a miniprotein radioconjugate targeting B7-H3, will enter Phase 1b mid-2026; pro forma cash $562M.

Media coverage

August 13 WTOP

Aktis: Q2 Earnings Snapshot

BOSTON (AP) — BOSTON (AP) — Aktis Oncology Inc. (AKTS) on Thursday reported a loss of $24.1 million in its second quarter. The Boston-based company...

June 26 The Globe and Mail

Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS)

Detailed price information for Aktis Oncology Inc (AKTS-Q) from The Globe and Mail including charting and trades.

June 18 Daily Political

Aktis Oncology (NASDAQ:AKTS) Shares Up 6.6% After Analyst Upgrade - Daily Political

Aktis Oncology (NASDAQ:AKTS – Get Free Report)’s share price was up 6.6% during trading on Tuesday after Raymond James Financial upgraded the stock to a...

May 21 MENAFN

Aktis Oncology Reports First-In-Human Clinical Imaging And Dosimetry Data For AKY-2519 Demonstrating Robust Tumor Uptake And Limited Normal Tissue Exposures In Patients With B7 ...

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3...

Never miss news about Aktis Oncology

Track Aktis Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aktis Oncology competitors & trending companies

Browse news for competitors to Aktis Oncology and other trending companies.